<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894110</url>
  </required_header>
  <id_info>
    <org_study_id>EMME-001</org_study_id>
    <nct_id>NCT04894110</nct_id>
  </id_info>
  <brief_title>Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema</brief_title>
  <official_title>A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 With and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emmecell</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emmecell</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal edema is the most common indication for corneal transplantation, accounting for&#xD;
      approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK)&#xD;
      procedures annually. There is currently no disease-modifying treatment for corneal edema.&#xD;
      Topical treatments like hypertonic saline are not effective on a long-term basis. For those&#xD;
      with advanced disease, where edema and vision loss are not controlled by topical treatment,&#xD;
      the only option is a corneal transplant. A potential approach to avoidance of the risks of&#xD;
      corneal transplantation is to inject cultured human corneal endothelial cells (HCECs) into&#xD;
      the anterior chamber of the eye. This approach may avoid surgery by re-populating the inner&#xD;
      most aspect of the cornea with functioning endothelial cells. Emmecell has developed a&#xD;
      treatment based on technology integrating biocompatible magnetic nanoparticles with cultured&#xD;
      HCECs to treat corneal edema in a minimally invasive way. The primary objective of this phase&#xD;
      1, prospective, multi-center, open-label, dose-escalation study is to evaluate the safety and&#xD;
      tolerability of 3 doses of EO2002 with and without endothelial brushing (EB) or Descemet&#xD;
      Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that&#xD;
      qualify for surgery involving full-thickness corneal transplantation or EK.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 1, prospective, multi-center, open-label, dose-escalation study is designed to&#xD;
      evaluate the safety and tolerability of EO2002 with and without endothelial brushing (EB) or&#xD;
      Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial&#xD;
      dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK.&#xD;
      Three doses will be studied in approximately 18 study participants that meet the&#xD;
      inclusion/exclusion criteria. Safety and tolerability will be the primary focus for 26 weeks&#xD;
      following treatment with EO2002.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label, Dose-Escalation Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability of EO2002]</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability of EO2002 (+/- EB or Descemet Stripping)] in subjects with corneal edema at week 26.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of EO2002 (+/-EB or DS) on corneal thickness</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Evaluate the effect of a single injection of EO2002 (+/-EB or DS) on corneal thickness as determined by pachymetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of EO2002 (+/-EB or DS) on best corrected visual acuity (BCVA).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Evaluate the effect of a single injection of EO2002 (+/-EB or DS) on best corrected visual acuity (BCVA) as determined by ETDRS letter score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Corneal Edema</condition>
  <condition>Corneal Endothelial Dysfunction</condition>
  <condition>Corneal Endothelial Dystrophy</condition>
  <condition>Fuchs Dystrophy</condition>
  <condition>Fuchs Endothelial Corneal Dystrophy</condition>
  <condition>Pseudophakic Bullous Keratopathy</condition>
  <condition>Bullous Keratopathy</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Moderate Corneal Endothelial Decompensation</condition>
  <arm_group>
    <arm_group_label>EO2002 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EO2002</intervention_name>
    <description>EO2002 (magnetic human corneal endothelial cells [HCECs]) with and without endothelial brushing (EB) or Descemet Stripping (DS)</description>
    <arm_group_label>EO2002 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All ocular criteria apply to study eye unless otherwise noted.&#xD;
&#xD;
          1. Age â‰¥ 21 years.&#xD;
&#xD;
          2. Phakic or Pseudophakic with a posterior chamber intraocular lens&#xD;
&#xD;
          3. Symptomatic corneal edema associated with endothelial dysfunction which may be&#xD;
             secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All ocular criteria apply to study eye unless otherwise noted.&#xD;
&#xD;
          1. Other corneal disease&#xD;
&#xD;
          2. Anterior chamber intraocular lens, Sutured or scleral-fixated intraocular lens.&#xD;
&#xD;
          3. Macular disease that in the investigator and/or sponsor's opinion would limit the&#xD;
             ability of the subject to demonstrate improvement in BCVA.&#xD;
&#xD;
          4. History of refractive surgery.&#xD;
&#xD;
          5. Descemet membrane detachment.&#xD;
&#xD;
          6. History of uveitis or other ocular inflammatory disease.&#xD;
&#xD;
          7. History of glaucoma or ocular hypertension, incisional glaucoma surgery in either eye&#xD;
             or prior glaucoma laser procedures in either eye&#xD;
&#xD;
          8. Prior incisional eye surgery within 3 months prior to study treatment or penetrating&#xD;
             or endothelial keratoplasty.&#xD;
&#xD;
          9. History of ocular neoplasm.&#xD;
&#xD;
         10. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200).&#xD;
&#xD;
         11. Female who is pregnant, nursing, or planning to become pregnant, or who is of&#xD;
             childbearing potential and not using a reliable means of contraception during the&#xD;
             study.&#xD;
&#xD;
         12. Subject is currently participating in or has participated within the last 3 months in&#xD;
             any other clinical trial of an investigational drug by ocular or systemic&#xD;
             administration.&#xD;
&#xD;
         13. Any concomitant medical or psychological condition that could interfere with study&#xD;
             participation or is otherwise not suitable for entry into the study in the opinion of&#xD;
             the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noelia Kunzevitzky</last_name>
    <role>Study Director</role>
    <affiliation>Emmecell</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmecell Study Contact</last_name>
    <phone>650-769-4232</phone>
    <email>clinicaltrials@emmecell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Diego Location</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>650-769-4232</phone>
      <email>clinicaltrials@emmecell.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Location</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>650-769-4232</phone>
      <email>clinicaltrials@emmecell.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palm Beach Gardens Location</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>650-769-4232</phone>
      <email>clinicaltrials@emmecell.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Des Moines Location</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>650-769-4232</phone>
      <email>clinicaltrials@emmecell.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City Location</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>650-769-4232</phone>
      <email>clinicaltrials@emmecell.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

